Volume 25, Issue 5 (Iranian South Medical Journal 2023)
Iran South Med J 2023, 25(5): 466-474 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahimlou S, Rezaei S, Milanchian N, Gharepapagh E. Evaluation of Radioiodine Therapy in the Refractory Hyperthyroidism. Iran South Med J 2023; 25 (5) :466-474
URL: http://ismj.bpums.ac.ir/article-1-1661-en.html
URL: http://ismj.bpums.ac.ir/article-1-1661-en.html
1- Internal Medicine Department, Medical School, Islamic Azad University of Medical Sciences, Tabriz Branch, Tabriz, Iran
2- Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, Iran
3- Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, Iran ,esmaeil.gharepapagh@gmail.com
2- Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, Iran
3- Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, Iran ,
Abstract: (1488 Views)
Background: Thyrotoxicosis is a clinical state with potentially multiple etiologies, clinical presentations, and treatments. Thyrotoxicosis is a clinical condition that results from inappropriate function of thyroid hormone in the body tissues. During the early 1950s, radioactive iodine was used as a definitive treatment method. During the last two decades, radioactive iodine has been recognized as an effective treatment for thyrotoxicosis because of its simplicity, repeatability, inexpensiveness, and low recurrence rate.
Method and materials: One hundred patients with refractory hyperthyroidism (40 men and 60 women) were enrolled according to the inclusion criteria from 2017 to 2021. The data was extracted considering the ethical principles of examining patients' medical files. Patients' information including age, gender, type of hyperthyroidism, serum levels of TSH, and free T4 were collected before and 2, 6, and 12 months after treatment.
Results: The results showed that 61% of the patients had toxic nodular goiter and 39% had diffuse toxic goiter. The mean ± standard deviation values of patient’s TSH and free T4 before treatment were 0.91±0.07 and 2.9±0.8, respectively. Six months after treatment, 49% of the patients became hypothyroid. Also 43% revealed euthyroid state and 5% showed no response (recurrence). One year follow-up of these patients after repetitive radioiodine therapy showed 6% hypothyroidism and 2% euthyroidism.
Conclusion: Our results indicated that radioactive iodine therapy is an effective and definitive treatment for patients with refractory hyperthyroidism.
Method and materials: One hundred patients with refractory hyperthyroidism (40 men and 60 women) were enrolled according to the inclusion criteria from 2017 to 2021. The data was extracted considering the ethical principles of examining patients' medical files. Patients' information including age, gender, type of hyperthyroidism, serum levels of TSH, and free T4 were collected before and 2, 6, and 12 months after treatment.
Results: The results showed that 61% of the patients had toxic nodular goiter and 39% had diffuse toxic goiter. The mean ± standard deviation values of patient’s TSH and free T4 before treatment were 0.91±0.07 and 2.9±0.8, respectively. Six months after treatment, 49% of the patients became hypothyroid. Also 43% revealed euthyroid state and 5% showed no response (recurrence). One year follow-up of these patients after repetitive radioiodine therapy showed 6% hypothyroidism and 2% euthyroidism.
Conclusion: Our results indicated that radioactive iodine therapy is an effective and definitive treatment for patients with refractory hyperthyroidism.
Keywords: Radioactive iodine therapy, hyperthyroidism resistant to therapy, hypothyroidism, euthyroidsm
Type of Study: Original |
Subject:
Endocrine System
Received: 2022/11/28 | Accepted: 2022/12/31 | Published: 2023/02/19
Received: 2022/11/28 | Accepted: 2022/12/31 | Published: 2023/02/19
References
1. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26(10): 1343-1421. [DOI]
2. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273(10): 808-12. [PubMed]
3. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331(19): 1249-52. [DOI]
4. Holm LE. Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951- 1975. J Nucl Med 1982; 23(2): 108-12. [PubMed]
5. Abraham-Nordling M, Torring O, Hamberger B, et al. Graves' disease: a long-term qualityof-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005; 15(11): 1279-1286. [DOI]
6. Ahmadzadehfar H. Clinical Nuclear Medicine. In: Biersack HJ, Freeman L, Zuckier L, editors. 2nd ed. Berlin: Springer, 2020, 1038. [Article]
7. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21(6): 593-646. [DOI]
8. Hegedus L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24(1): 102-132. [DOI]
9. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33(6): 920-980. [DOI]
10. Zingrillo M, Urbano N, Suriano V, et al. Radioiodine treatment of Plummer and multinodular toxic and nontoxic goiter disease by the first approximation dosimetry method. Cancer Biother Radiopharm 2007; 22(2): 256-260. [DOI]
11. Erkan ME, Demirin H, Asik M, et al. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res 2012; 24(6): 714-717. [DOI]
12. Assadi M. clinician’s Guide to Nuclear Endocrinology; Applied Molecular imaging and Radionuclide Therapies. 2nd ed. Bushehr: Bushehr University of Medical Sciences and Health Services, 2018, 344. [Article]
13. Bonnema SJ, Hegedius L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes 2009; 16(5): 379-384. [DOI]
14. Bolkheir AR, Ostovar A, Moradinasab M, et al. Nuclear Radiation and Thyroid Cancer; A Systematic Review. Iran South Med J 2022; 25(3): 261-276. (Persian) [Article]
15. Meier DA, Kaplan MM. Radioiodine uptake and thyroid scintiscanning. Endocrinol Metab Clin North Am 2001; 30(2): 291-313, viii. [DOI]
16. Onimode YA, Dairo DM, Ellmann A. Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men. Pan Afr Med J 2018; 29: 48. [DOI]
17. Enyi Ejeh MJ, Omotayo Ogunjobi K, Enyi Ejeh J, et al. Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria. Mol Imaging Radionucl Ther 2013; 22(2): 36-41. [DOI]
18. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed) 1984; 289(6441): 361-3. [DOI]
19. Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine treatment of hyperthyroidismprognostic factors for outcome. J Clin Endocrinol Metab 2001; 86(8): 3611-7. [DOI]
20. Ahmad T, Khoja A, Rashid NH, et al. Outcome of radioactive iodine therapy in Toxic Nodular Goiter in Pakistan. Pak J Med Sci 2018; 34(5): 1146-1151. [DOI]
21. Husseni MA. The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves' Disease and the Predictive Factors Influencing its Development. World J Nucl Med 2016; 15(1): 30-7. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
